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GDNF Induces a Dystonia-like State
in Neonatal Rats and Stimulates Dopamine
and Serotonin Synthesis
Klaus D. Beck,*² Ian Irwin,³ Janet Valverde,* (Hoffer et al., 1994; Beck et al., 1995; Kearns and Gash,
1995; Sauer et al., 1995; Tomac et al., 1995a). In theThomas J. Brennan,* J. William Langston,³
CNS, the pattern of GDNF mRNA expression stronglyand Franz Hefti*
suggests a role for this factor in the development of*Department of Neuroscience
the nigrostriatal projection. During dopaminergic axonGenentech Incorporated
outgrowth and initial target innervation in developingSouth San Francisco, California 94080
rats (embryonic day 15.5 [E15.5]) GDNF mRNA is ex-³Parkinson's Institute
pressed in the ventral mesencephalon in close proximitySunnyvale, California 94086
to the dopaminergic neurons. GDNF mRNA transcripts
are also expressed outside the CNS, suggesting possi-
ble functions during oraganogenesis, innervation, orSummary
both (Suter-Crazzolara and Unsicker, 1995). During
postnatal development, GDNF mRNA is undetectable inTo test whether glial cell line±derived neurotrophic
the mesencephalon, but is transiently expressed in thefactor (GDNF) regulates the development of nigral do-
striatum, the innervation target of nigral dopaminergicpaminergic neurons in vivo, neonatal rats received bi-
neurons (Schaar et al., 1993; Stroemberg et al., 1993;lateral injections of GDNF into the striatum. Injections
Poulsen et al., 1994). In adult rat brain, GDNF mRNA isat postnatal day 2 induced a unique transient behav-
undetectable, but its expression can be induced by lim-ioral pattern characterized by forelimb hyperflexure,
bic motor status epilepticus in striatum, hippocampus,clawed toes of all limbs, and a kinked tail. Parallel to
and cortex (Schmidt-Kastner et al., 1994; Ho et al., 1995).the behavioral changes, the levels of striatal and ven-
A recent report demonstrated retrograde transport oftral mesencephalic dopamine and serotonin were in-
iodinated GDNF to nigral dopaminergic neurons follow-creased from 60% to 100% with a proportional in-
ing injection into the striatum of adult rats (Tomac et al.,crease of principal metabolite levels. GDNF increased
1995b).tyrosine hydroxylase activity in the ventral mesen-
The GDNF mRNA expression pattern suggests thatcephalon, but did not affect striatal activity of choline
striatal GDNF regulates the maturation of dopaminergicacetyltransferase and GABA uptake. GDNF failed to
terminals in this target area. To test this hypothesisinduce sprouting of dopaminergic neurites. Our find-
directly, we increased striatal GDNF levels during post-ings suggest that during development striatal GDNF
natal development by injecting rat recombinant GDNFregulates the capacity of dopaminergic and of sero-
into this brain area. The initial observations revealed
tonergic neurons for neurotransmitter production and
striking behavioral consequences that were then found
release.
to be associated with the augmentation of biochemical
parameters of dopaminergic and serotonergic neuron
function.
Introduction
Results
Dopaminergic neurons in the ventral mesencephalon
play a crucial role in the regulation of motor function, Single bilateral injections of 10 mg of GDNF (5 mg each
and there is evidence for their involvement in cognitive side) into the striatum of postnatal day 2 (P2) rats pro-
processes. The degeneration of dopaminergic neurons duced a striking and unique pattern of behavioral
represents the defining feature of Parkinson's disease. changes (Figure 1). Most prominent was the smaller size
The development of this neuronal population has been of GDNF injected rats and the appearance of hyper-
described in detail in the rat. Initial innervation of the flexed forelimbs that was maintained during all behav-
principal target areas (striatum, nucleus accumbens, ol- ioral activities (Figures 1A, 1E, and 1F). When lifted up,
factory tubercle, and cortex) occurs prenatally. The pro- GDNF injected pups did not extend their forelimbs to-
jection matures during the first 2 weeks postnatally and ward a surface as normal animals do (Figure 1B). A
exhibits a gradual increase in terminal density in the second obvious GDNF-induced behavioral difference
target areas toward adult levels (Specht et al., 1981a, related to the appearance of the tails of the rats. Tails
1981b; Voorn et al., 1988; Broaddus and Bennett, 1990; of pups injected with a control protein showed a smooth
Arbogast and Voogt, 1991). curvature of the tail as did uninjected rats (Figures 1A
A number of growth factors have been found to in- and 1C). In contrast, GDNF injected rats showed multiple
crease survival or differentiation (or both) of cultured kinks in their tails, reflecting increased muscle tension
embryonic dopaminergic neurons (Beck, 1994; Poulsen (Figures 1A and 1D). Third, GDNF injected animals kept
et al., 1994; Krieglstein and Unsicker, 1994); however, their toes in a clawed position (Figures 1A, 1D, and 1F).
glial cell line±derived neurotrophic factor (GDNF) has This phenomenon was observed both at forelimbs and
been the only factor significantly protecting dopaminer- hindlimbs. There was no obviousdifference in locomotor
gic neurons from lesion-induced degeneration in vivo activity between GDNF injected and control rats; how-
ever, control rats were more successful in gaining ac-
cess to suckle. There were no obvious behavioral differ-²Present address: Idun Pharmaceuticals, 11085 Torrey Pines Road,
Suite 300, La Jolla, California 92037. ences between animals receiving control protein
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(P2) was given unilateral striatal injections of 5 mg GDNF.
Different from rats with bilateral injections, these unilat-
erally injected rats developed hyperflexure limited to
the forelimb and, to a lesser degree, also the hindlimb
contralateral to the injected side without an effect on
the ipsilateral side (Figure 1G). In contrast with neonatal
rats, adult rats receiving single GDNF injections (10 mg)
into the striatum or above the substantia nigra were
unaffected in posture and behavior. Also the levels of
dopamine, serotonin, and their respective metabolites
were unaffected (Table 1).
GDNF-treated neonatal rats showed a slower rate of
weight increase compared with cytochrome C injected
and uninjected controls. There were significant differ-
ences in weight between GDNF-treated and control
groups at 6 and 12 days (P8 and P14) after the intrastria-
tal injections (Figure 2). In parallel to the behavioral
changes, the weight differences were no longer evident
26 days after the injections (P28).
To test for the hypothesis that the behavioral changes
reflect alterations in the function of nigrostriatal neurons,
we measured several biochemical and morphological
dopaminergic parameters. Levels of striatal and ventral
mesencephalic dopamine (DA) at P8 were increased by
60% and 100%, respectively, in GDNF-treated animals
as compared with cytochrome C injected controls (Table
1). At P14, the increases were reduced to 25% and 37%,
respectively, and at P28, no significant difference could
be detected. Levels of the principal DA metabolites,
DOPACand HVA, were increased proportionally to those
of dopamine itself. Striatal and ventral mesencephalic
levels of serotonin (5-HT) and its metabolite hydroxyin-
dolaceticacid (HIAA) were increased by GDNF in parallel
to the increases seen in DA and its metabolites (Table
1). Compared with cytochrome C injected rats, at P8Figure 1. Increased Muscle Tonus Following Intrastriatal Injection
the striatal and ventral mesencephalic levels of 5-HTof GDNF
were increased by 85% and 95%, respectively. At P14Shown are rat pups at P8 that had received bilateral intrastriatal
in GDNF injected rats, striatal 5-HT levels were not sig-injections of GDNF at P2.
(A) Comparison to a cytochrome C injected littermate (bottom). Note nificantly different from those in cytochrome C injected
reduced body size and hyperflexed forelimbs in GDNF injected pup. controls, but there was a 28% increase in the mesen-
(B) When lifted up, GDNF injected pupsdo not extend their forelimbs. cephalon. At P28, no significant differences could be
(C±G) Tails of cytochrome C injected pups are smoothly curved (C),
detected. Bilateral GDNF injection into the midbrainwhile GDNF injected rats show multiple kinks and toes are kept in
above the substantia nigra produced increases of DA,a clawed position (D). Close up of forelimbs show normal positioning
5-HT, and metabolites in P8 striatum and ventral mesen-(E) and hyperflexion after GDNF injection (F); forelimbs were kept
in this position during all activities. Unilateral striatal GDNF injections cephalon similar to those seen after striatal administra-
induce contralateral forelimb hyperflexion (G). tion (Table 1).
Figure 3 shows the results of a dose-response analy-
sis of the GDNF effect on tissue DA (Figure 3A) and 5-
injections and uninjected controls. The behavioral HT levels (Figure 3B) at P8. Striatal injection of 0.05 mg
changes became evident 3±4 days after the injections of GDNF did not affect DA levels, while 0.5 mg increased
(P5±P6) and were most evident in the period between DA by 25% and 29% above levels measured in striatum
6±12 days after the injections (P8±P14). They gradually and ventral mesencephalon, respectively, of animals in-
declined in intensity thereafter and were no longer pres- jected with control protein. Following 5 mg of GDNF,
ent 26 days after the GDNF injections (P28). Rats in- striatal DA was increased by 57% and mesencephalic
jected with 5 mg of GDNF could not be behaviorally dopamine by 95%. DOPAC and HVA levels were in-
distinguished from rats injected with 10 mg. While ad- creased proportionally (data not shown). 5-HT levels
ministration of 0.05 mg of GDNF did not produce behav- were increased by GDNF in a similar fashion (Figure 3B):
ioral changes, rats injected with 0.5 mg displayed slight 0.05 mg of GDNF produced no significant changes, 0.5
paw clawing and tail kinking, but no forelimb hyperflex- mg increased striatal and mesencephalic 5-HT by 37%
ion (data not shown). Bilateral injection of a total of and 45%, respectively, while 5 mg of GDNF produced a
10 mg of GDNF above the substantia nigra of P2 rats maximal increase of 55% and 88%, respectively. HIAA
produced identical transient behavioral changes (data levels were increased proportionally (data not shown).
To test whether the increased DA levels reflect thenot shown). In addition, one group of neonatal animals
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Table 1. Tissue Levels of DA, 5-HT, and Metabolites Following GDNF Injections into the Striatum or above Substantia Nigra in Neonatal
(5 mg, Bilateral) and in Adult Rats (10 mg, Unilateral)
Test DA DOPAC HVA 5-HT HIAA
P8,striatal injection
Striatum
Control (10) 40.11 6 4.34 6.22 6 0.57 6.24 6 0.80 2.50 6 0.26 4.51 6 0.32
Cytochrome C (10) 31.50 6 7.20 5.80 6 0.85 6.55 6 0.70 2.55 6 0.23 4.19 6 0.58
GDNF (10) 52.98 6 4.16b 8.65 6 0.75b 9.87 6 0.71b 4.72 6 0.39b 7.82 6 0.70b
Mesencephalon
Control 11.44 6 1.03 6.52 6 0.65 6.26 6 0.85 9.51 6 1.07 15.97 6 1.69
Cytochrome C 8.43 6 1.05 4.41 6 0.41 4.20 6 0.47 8.47 6 0.61 13.20 6 1.42
GDNF 16.89 6 1.31b 7.29 6 0.69b 7.87 6 0.60b 16.55 6 1.70b 24.01 6 2.04b
P14,striatal injection
Striatum
Control (6) 61.71 6 4.66 13.47 6 0.59 13.80 6 0.88 2.92 6 0.32 10.14 6 0.75
Cytochrome C (6) 57.46 6 6.86 12.19 6 1.30 14.94 6 1.20 3.55 6 0.34 9.41 6 0.80
GDNF (6) 72.05 6 5.01b 14.23 6 1.23 14.05 6 1.64 3.80 6 0.30 10.31 6 1.02
Mesencephalon
Control 13.28 6 0.88 6.22 6 0.70 7.82 6 0.68 16.39 6 1.36 23.61 6 1.84
Cytochrome C 14.24 6 2.63 6.22 6 0.88 6.88 6 0.98 14.10 6 1.03 20.16 6 1.45
GDNF 19.50 6 1.39b 9.86 6 1.75b 9.25 6 1.12a 18.04 6 1.69a 24.59 6 2.31a
P28, striatal injection
Striatum
Control (6) 72.45 6 4.64 16.29 6 2.89 14.10 6 0.40 5.65 6 0.61 13.16 6 1.73
Cytochrome C (6) 72.71 6 5.60 16.46 6 2.43 13.16 6 1.60 5.98 6 0.51 11.66 6 1.07
GDNF (6) 70.12 6 7.54 16.81 6 2.44 13.11 6 1.60 7.00 6 0.56 12.74 6 1.26
Mesencephalon
Control 9.49 6 1.02 4.33 6 0.21 4.39 6 0.40 15.07 6 1.46 33.76 6 3.12
Cytochrome C 8.14 6 1.01 4.10 6 0.31 4.70 6 0.23 13.29 6 1.19 29.35 6 2.37
GDNF 10.89 6 1.09 4.19 6 0.35 4.46 6 0.57 15.40 6 1.62 34.38 6 3.34
P8, supranigral injection
Striatum
Cytochrome C (5) 40.80 6 3.98 5.65 6 0.41 6.01 6 0.52 3.06 6 0.30 7.64 6 0.70
GDNF (5) 69.93 6 5.92b 8.84 6 0.66b 8.99 6 0.88b 4.43 6 0.32b 10.46 6 0.98b
Mesencephalon
Cytochrome C 9.04 6 1.02 5.30 6 0.36 4.74 6 0.35 10.14 6 1.18 18.70 6 2.03
GDNF 16.94 6 1.53b 8.46 6 0.48b 7.66 6 0.71b 15.19 6 0.96b 25.67 6 2.37b
Adult, 21 days after unilateral striatal injection
Striatum
Cytochrome C (4)
Control side 85.33 6 7.53 15.04 6 2.01 8.94 6 0.55 18.98 6 1.44 18.12 6 1.66
Injected side 86.80 6 8.88 14.54 6 1.22 8.65 6 0.80 19.24 6 1.86 18.81 6 1.98
GDNF (4)
Control side 84.45 6 5.62 16.00 6 1.22 8.66 6 0.72 18.36 6 1.28 18.88 6 1.94
Injected side 86.68 6 7.55 14.81 6 1.31 8.50 6 0.52 18.33 6 1.86 18.01 6 1.22
Mesencephalon
Cytochrome C (4)
Control side 9.42 6 1.00 4.12 6 0.33 4.09 6 0.39 38.89 6 3.91 42.03 6 4.10
Injected side 10.02 6 0.96 4.20 6 0.40 4.23 6 0.32 39.92 6 3.12 45.41 6 4.33
GDNF (4)
Control side 10.22 6 0.99 4.45 6 0.40 4.22 6 0.49 41.74 6 3.99 43.11 6 4.58
Injected side 9.89 6 0.88 4.34 6 0.41 4.24 6 0.28 42.99 6 3.84 42.98 6 3.97
Adult, 21 days after unilateral nigral injection
Striatum
Cytochrome C (4)
Control side 82.53 6 3.62 14.07 6 1.44 8.44 6 1.19 20.06 6 1.68 18.89 6 1.69
Injected side 78.62 6 3.88 13.92 6 0.24 9.10 6 0.57 19.70 6 1.31 18.19 6 1.64
GDNF (4)
Control side 82.99 6 7.11 14.04 6 0.35 8.48 6 0.47 21.15 6 1.81 18.19 6 1.64
Injected side 79.92 6 4.47 12.61 6 0.81 8.57 6 0.50 20.06 6 1.50 18.99 6 1.65
Mesencephalon
Cytochrome C (4)
Control side 10.24 6 0.90 4.42 6 0.39 4.10 6 0.39 41.03 6 4.04 41.72 6 4.00
Injected side 10.89 6 1.02 4.68 6 0.41 4.22 6 0.41 39.21 6 3.00 40.35 6 3.10
GDNF (4)
Control side 10.66 6 1.14 4.55 6 0.44 4.31 6 0.36 39.98 6 1.10 42.09 6 2.39
Injected side 11.44 6 1.10 4.68 6 0.43 4.28 6 0.40 42.41 6 4.27 45.42 6 3.28
All values are given as mean 6 SEM (in ng/mg of protein). Number of animals per group are indicated in parentheses. Footnotes indicate
statistically significant difference compared with corresponding cytochrome C injected group (ap , 0.01; bp , 0.001; Student's t test).
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Figure 3. GDNF Dose-Response Analysis
DA (A) and 5-HT (B) levels in P8 rats after bilateral striatal injection
of GDNF. Equal volumes of GDNF dilutions were injected at P2, and
DA/5-HT levels were determined in P8 striata and ventral mes-
encephali as described in Experimental Procedures. Asterisks indi-Figure 2. Postnatal Increase in Body and Brain Weights
cate statistically significant differences from corresponding control
Data for body (A) or brain (B) weights from control rats (closed and cytochrome C groups (one asterisk, p < 0.05; two asterisks,
bars) and from rats following injection of GDNF (dotted bars) or p < 0.01; Student's t test). P8 rats injected with 0.05 mg GDNF
cytochrome C (hatched bars). Asterisks indicate statistically signifi- did not show any behavioral changes, those injected with 0.5 mg
cant differences from corresponding control and cytochrome C displayed slight paw clawing and tail kinking, but no forelimb hyper-
groups (one asterisk, p < 0.05; two asterisks, p < 0.01; Student's t flexion. The group injected with 5 mg GDNF showed the fulldystonia-
test). like pattern seen after 10 mg GDNF.
[3H]Mazindol-binding site density served as an addi-induction of synthesizing enzyme in dopaminergic neu-
tional parameter to test for changes in dopaminergicrites, we measured tyrosine hydroxylase activity in stria-
terminal density (Javitch et al., 1984). This parametertum and ventral mesencephalon of GDNF injected
was moderately increased by GDNF at P8 (40%, Tableanimals and visualized this enzyme with immunohisto-
5), but was back to control levels by P14, when thechemical methods. An increase in tyrosine hydroxylase
behavioral changes still were maximal. The absence of(TH) activity (48%) was found in the mesencephalon but
strong changes of mazindol-binding site density andnot striatum (Table 2). The activity of choline acetyltrans-
density of TH-positive fibers in the striatum does notferase (ChAT, a marker enzyme for striatal cholinergic
support theview that themore robust increases in dopa-interneurons) in striatal tissue and g-aminobutyric acid
mine levels reflect sprouting of nigrostriatal terminals.(GABA) uptake into striatal synaptosomes were not
affected by GDNF administration (Table 3).
No differences between GDNF-treated and control
Table 2. Tyrosine Hydroxylase Activity after Intrastraital GDNF
animals were observed in TH staining pattern and inten- Injections (5 mg, Bilateral) into Neonatal Rats
sity, failing to support the hypothesis that GDNF stimu-
Tissue Control (9) Cytochrome C (7) GDNF (7)lates sprouting of dopaminergic neurites (Figure 4). Ab-
Striatum 79.17 6 6.88 75.35 6 7.98 82.79 6 7.56errant TH-immunopositive fibers were not found in any
Mesencephalon 80.69 6 8.14 77.46 6 5.62 115.09 6 6.85abrain area,excluding thepossibility of significant sprout-
ing of dopaminergic neurites into nontarget areas. The Values are means 6 SEM (in pmol of DOPA/mg of protein/min) from
tissues at P8; numbers of rats per group are indicated in parenthe-numbers and average cell body sizes of mesencephalic
ses.TH-positive neurons were not affected by GDNF treat-
a Statistically significant difference compared with correspondingment (Table 4).
cytochrome C injected group (p , 0.001; Student's t test).
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Table 3. Striatal ChAT Activity and GABA Uptake after Intrastriatal GDNF Injections (5 mg, Bilateral) into Neonatal Rats
Test Control Cytochrome C (5) GDNF (8)
ChAT activity 9.60 6 0.81 (6) 8.76 6 0.75 (5) 9.51 6 0.59 (8)
[3H]GABA uptake 251.2 6 12.1 (4) 239.2 6 18.8 (5) 244.5 6 20.3 (5)
Values are means 6 SEM (in pmol of ACh or [3H]GABA/mg of protein/min) from tissues at P8; numbers of rats per group are indicated in
parentheses.
Also the the distribution and density of 5-HT immuno- pattern is reminiscent of the clinical condition dystonia,
which is characterized by muscular hypertonus and ri-staining in the striataum and ventral mesencephalon
was unaffected by GDNF (data not shown). gidity (Adams and Victor 1993). Dystonia is a CNS dys-
function rather than a disorder of muscles. There are
hereditary and idiopathic forms of dystonia, and theDiscussion
disorder can be generalized or limited to specific muscle
groups. The etiologies of the different clinical forms ofThe unique behavioral pattern induced by GDNF injec-
tions into the striatum of neonatal rats represents the dystonia are largely unclear, but a possible involvement
of dopaminergic mechanisms has been proposed basedmost significant finding of the present study. GDNF in-
duced transient hyperflexure of forelimbs and the ap- on the fact that patients suffering from generalized
dystonias usually get some symptomatic relief frompearance of clawed toes and kinked tails.The behavioral
alterations were associated with increases in DA levels treatment with centrally acting dopamine antagonists,
muscarinic agonists, or in more progressed cases, withbut not markers of dopaminergic fiber density, sug-
gesting that they were caused by increased DA metabo- L-DOPA (Adams and Victor, 1993).
Our biochemical analysis showed effects of GDNFlism rather than sprouting of dopaminergic terminals.
The transient increase in DA levels was accompanied by on dopaminergic and, in addition, also on serotonergic
neurons. Both transmitter systems are interacting exten-a parallel elevation of 5-HT tissue levels, but no altered
distribution of 5-HT immunostaining. sively as suggested by the reciprocal anatomical projec-
tions between dopaminergic neurons in substantia ni-The combination of behavioral changes induced by
intrastriatal GDNF has not been described before. The gra/VTA and serotonergic neurons in the dorsal raphe
Figure 4. TH Immunostaining
Coronal brain sections at corresponding levels of striatum (A and C) and mesencephalon (B and D) of P8 rats following injection of cytochrome
C (A and B) or GDNF (C and D). Pattern and intensity of TH staining is not significantly different; there was no aberrant TH staining throughout
the brain.
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we cannot completely exclude a potential direct actionTable 4. Numbers and Cell Body Sizes of Nigral TH-Positive
Neurons after Neonatal GDNF Administration of GDNF also on serotonergic neurons.
In contrast with the findings in neonatal rats, in adultNumber of Nigral
rats with single unilateral injections of 10 mg of GDNFTH-Positive
into the striatum or above the substantia nigra, we didGroup Neurons Cell Body Size (mm2)
not observe a significant weight loss (data not shown),Control (5) 12,944 6 843 80.9 6 3.2
no change in nigral and striatal TH immunoreactivity, noCytochrome C (5) 12,252 6 710 80.2 6 4.5
sprouting of TH-positive fibers toward the injection site,GDNF (6) 12,452 6 907 83.1 6 3.9
and no change in DA or 5-HT synthesis or turnover.
Values are means 6 SEM of cell counts from both sides with each
These results are in contrast with data reported by Hud-sixth section used for analysis and multiplication of the result by
son et al. (1995). For our studies, we used adult (240±250six. Average cell sizes were determined from ten randomly selected
nigral TH-positive neurons per rat and per three corresponding lev- g) Fisher 344 and Wistar rats (data not shown), and for
els (30 cells per rat in total). Number of rats per group is indicated the supranigral injections, we followed the coordinates
in parentheses. and injection protocol described by Hudson et al. (1995).
In addition to the lack of sprouting of TH-positive fibers
in this study, we had reported earlier that repeated nigral
GDNF injections did not affect the numbers of mesence-nucleus (DRN; Dray et al., 1976; Pasquier et al, 1977;
Azmitia and Segal, 1978; Herve et al., 1987; Kalen et al., phalic TH-immunopositive neurons and did not induce
dopaminergic neuron sprouting in normal unlesioned1988; Nedergaard et al., 1988; Van Bockstaele et al.,
1993). Pharmacological interactions between both animals (Beck et al., 1995). However, Hudson et al. (1995)
did not provide any information about the actual weighttransmitter systems have been studied extensively us-
ing DA and 5-HT agonists and antagonists and intracran- or age of their experimental animals. A grossly different
weight of the rats used in their studies compared withial microdialysis probes in freely moving rats, but the
results were rather controversial (Benloucif and Gallo- our animals would be likely to result in slightly different
actual injection sites using identical stereotaxic coordi-way, 1991; Huang and Nichols, 1993; Ferre et al., 1994;
Yadid et al., 1994; Dewey et al., 1995). Iontophoretic nates. In addition, if the rats used by Hudson et al. (1995)
were significantly younger, mesencephalic dopaminer-administration of 5-HT to the SN reduced electrical activ-
ity of nigral dopaminergic neurons, and electrical stimu- gic neurons could still be partially responsive to GDNF,
or if they were much older, it might be possible that theylation of the DRN has been reported to both activate
and inhibit SN neurons (Dray et al., 1978). Recently, had regained responsiveness. Recently, Tomac et al.
(1995b) reported retrograde transport of iodinatedusing positron emission tomography in baboons, Dewey
et al. (1995) reported data consistent with an inhibitory GDNF from striatum to nigral dopaminergic cell bodies
as well as GDNF immunoreactivity in dopaminergic neu-action of 5-HT on striatal DA release. However, the net
effect of 5-HT on dopaminergic neuron activity and DA rons in adult rats. Although these results suggest a role
for GDNF in adult rats, they do not provide direct evi-release might be dependent on the functional status of
dopaminergic neurons. In turn, there is also evidence dence.
Our behavioral findings in early postnatal rats are veryfor modulatory actions of DA on serotonergic neurons
in the DRN: increased DA levels in the DRN inhibit the different from those produced by drugs inducing acute
dopaminergic hyperfunction. Compounds such as am-activity of serotonergic neurons projecting to the stria-
tum via local 5-HT release and autoreceptor stimulation phetamine or cocaine, which induce the release of DA
and 5-HT, produce a general locomotor hyperactivity ofwithin the DRN. However, striatal and systemic adminis-
tration of dopaminergic agonists does not affect striatal animals. Similar locomotor activation is observed after
the injections of the DA precursor L-DOPA and of direct5-HT release (Ferre et al., 1994). These data, together
with the important finding that GDNF does not affect DA receptor agonists such as apomorphine (Greenberg
et al., 1974; Beninger, 1983; Bergman et al., 1989). Allserotonergic neurons cocultured with dopaminergic
neurons (Lin et al., 1993; Poulsen et al, 1994), suggest these drugs result in the continuous stimulation of DA
and 5-HT receptors, overriding the naturally occurringthat the primary action of GDNF in our study is on devel-
oping dopaminergic neurons. The concommittant in- transmitter release. GDNF injections resulted in robust
elevations of DA and 5-HT levels and of their metabolitescrease of 5-HT levels is most likely secondary and re-
flects an adaptive upregulation of serotonergic in striatum and substantia nigra, in absence of evidence
for morphological changes of nigrostriataldopaminergictransmitter synthesis inhibiting dopaminergic neuron
activity and DA release. However, based onour analysis, fibers and of serotonergic projections. The increase in
Table 5. Striatal [3H]Mazindol Autoradiography in Rats with Intrastriatal GDNF Injections (5 mg, bilateral)
Striatal Level Control (5) Cytochrome C (5) GDNF (5)
P8 0.84 6 0.04 0.77 6 0.07 1.08 6 0.06a
P14 2.12 6 0.19 2.22 6 0.13 2.25 6 0.20
P28 2.81 6 0.25 2.92 6 0.25 2.79 6 0.22
Values are means 6 SEM (in arbitrary OD units) obtained from sections at corresponding striatal levels. Slides were exposed to film, and OD
was analyzed as described in Experimental Procedures. Numbers of rats analyzed are indicated in parentheses.
a Statistically significant difference compared with corresponding cytochome C injected group (p , 0.01; Student's t test).
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mazindol binding at P8could bedue to a transient induc- 5-HT, but GDNF does not act primarily as a tropic factor
directing the developmental growth of dopaminergiction of DA uptake sites expression on dopaminergic
terminals. Elevated transmitter levels in absence of fibers.
sprouting indicate that existing terminals have a higher
capacity to synthesize and release DA and 5-HT. We Experimental Procedures
speculate that GDNF, rather than stimulating growth
GDNF Injectionsof dopaminergic neurites, increases the expression of
Rat recombinant GDNF was produced, purified, and tested for bio-specific genes of the transmitter machinery of dopamin-
logical activity as described previously (Beck et al., 1995). Neonatalergic and, as a secondary event, also of serotonergic
rats (P2, Wistar) were cold anesthesized and put on a custom-made
neurons. The fact that GDNF administration elevated TH stage (modeling clay) that fixed the rats in a prone position. The
activity supports this view. Thus, it seems likely that stage was positioned in a stereotaxic frame. For injections, the skin
over the skull was disinfected by wiping twice with 70% ethanol.GDNF injections as performed in the present study in-
Injections were done with Hamilton syringes into left and right striatacrease the capacity of dopaminergic and serotonergic
at the following locations: 2.0 mm posterior from an imaginary lineneurons to release DA/5-HT in response to physiological
connecting the posterior end of left and right eye, 1.5 mm left andstimuli by input neurons. The temporal pattern of stimu-
right from the midline, and 2.5 mm below the skin. At both sites, 5
lation of DA and 5-HT receptors in GDNF-treated ani- mg of GDNF or control protein (cytochrome C) in 2 ml of each (10
mals is very different from that of animals treated with mg in 4 ml total) of 0.9% saline with 10 mg/ml gentamicin at pH 7.4
were injected over 2 min. The location of the injections was verifieddirect or indirect agonists, explaining the behavioral dif-
in several control animals by injecting a 0.1% solution of trypan blueferences between the two types of treatments.
in 0.9% saline following this procedure. The trypan blue injectedThe slower weight gain in GDNF injected neonatal rats
animals were sacrificed by decapitation while still anesthesized im-was most likely related to reduced milk intake based on
mediately after the injection, and their brains were removed. Most
the disadvantage of these rats in gaining and main- of the trypan blue was found in the parenchyma of both striata with
taining access to suckle. With the disappearance of the traces in the cerebrospinal fluid (CSF) filling the lateral and third
ventricles. The presence of traces of trypan blue in the CSFdystonia-like muscle spasms after 2 weeks, the GDNF
prompted us initially to use bilateral striatal injections and separateinjected rats quickly caught up with the control groups.
control animals instead of using unilateral admininstration with theThe specificity of GDNF remains to be established.
contralateral side as control. In addition, a group of neonatal ratsBesides acting on dopaminergic and, indirectly, on sero-
received unilateral striatal injections of GDNF or cytochrome C. In
tonergic neurons, GDNF promotes survival and neurite these animals, the injections were given in smaller portions over 4
growth of cultured peripheral neurons (Buj-Bello et al., min to avoid leakage of the injected solutions into the CSF.
Bilateral nigral injections were done with Hamilton syringes at1995; Ebendal et al., 1995; Trupp et al., 1995) and in-
the following coordinates: 6.5 mm posterior from an imaginary linecreases the survival of chickand mammalian motor neu-
connecting the posterior end of left and right eye, 1.0 mm left androns in vitro and in vivo during development and follow-
right from the midline, and 2.5 mm below the skin. Injected volume,ing lesions (Henderson et al., 1994; Oppenheim et al.,
protein quantities, and duration of injection were identical to the
1995; Yan et al.,1995; Zurn et al, 1995). Results of studies ones described for striatal administration.
using polymerase chain reaction analysis suggest that Adult rats (Fisher 344, 240±250 g) were given single unilateral
injections of GDNF or control protein into the center of the striatumlow levels of GDNF mRNA are expressed in many CNS
as described by Venero et al. (1994), and immediately dorsal toareas, thus raising the possibility that GDNF might affect
the zona compacta of the substantia nigra following the methoddifferent CNS cells and multiple functions (Springer et
described by Hudson et al. (1995).al., 1994; Choi-Lundberg and Bohn, 1995; Ho et al.,
Injected rats were taken for biochemical and morphological analy-
1995). In particular for our study, it could be argued that sis at various intervals of time after the treatment. The anesthesized
the behavioral effects observed in the present study rats (50 mg/kg nembutal) weresacrificed by decapitation, andbrains
were removed onto ice. For biochemical and high pressure liquidreflect direct GDNF actions on motor neurons. However,
chromatography analysis, left and right striatum and ventral mesen-we can exclude this possibility based on our finding
cephalon (the area rostral of pons, caudal of the hypothalamus andthat unilateral striatal injections produced contralateral
anterior of the level of the aqueduct) were dissected. For [3H]mazin-behavioral effects. Transport of GDNF from the striatal
dol binding, brains were frozen in isopentane at2208C. Forhistologi-
injection site to spinal cord motor neurons would have to cal analysis, anesthesized rats were perfused transcardially with
occur via the cerebrospinal fluid through the ventricular phosphate-buffered saline (PBS) followed by 4% paraformaldehyde,
and brains were removed, postfixed for 12 hr, and then sunk in 100system. It is impossible that side-specificity could be
mM sodium phosphate (pH 7.4) with 25% sucrose and frozen.maintained during this process. There is further support
for a direct action of GDNF on nigral dopaminergic neu-
Analysis of Dopamine, Serotonin, and Metabolitesrons. Tomac et al. (1995b) demonstrated specific retro-
Ventral mesencephalon and combined left and right striatum weregrade transport of GDNF in rats from striatum to sub-
frozen in 0.1 M perchloric acid on dry ice. Levels of endogenous
stantia nigra. Additional data come from in vitro studies, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanilic
where it has been established that, in mesencephalic acid (HVA), serotonin (5-HT), and hydroxyindolaceticacid (HIAA) in
cultures, GDNF acts on dopaminergic neurons without these tissues were determined by a simultaneous assay using high
pressure liquid chromatography coupled to electrochemical detec-affecting serotonergic and GABAergic neurons (Lin et
tion using a modification of the procedure of Kilpatrick et al. (1986)al., 1993; Poulsen et al., 1994). However, it remains to
as described previously by Irwin et al. (1990).be established whether and which other neuron popula-
tions are directly responsive.
Enzyme Activities
Taken together, our results suggest that, during post- Dissected brain areas were homogenized and then frozen in distilled
natal developmentof thenigrostriatal dopaminergic pro- water. Tyrosine hydroxylase (TH) and choline acetyltransferase
jection, GDNF plays an important role in regulating do- (ChAT) activities and protein concentrations were as described by
Knusel et al. (1990).pamine synthesis, which in turn affects the synthesis of
Neuron
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[3H]GABA Uptake Broaddus, W.C., and Bennett, J.P., Jr. (1990). Postnatal develop-
ment of striatal dopamine function. I. An examination of D1 and D2The P2 synaptosome fraction of dissected and homogenized striatal
tissue was prepared as described by Lapchak et al. (1993). Specific receptors, adenylate cyclase regulation and presynaptic dopamine
markers. Dev. Brain Res. 52, 265±271.GABA uptake was determined using the protocol by Casper et al.
(1991), as the fraction of uptake sensitive to 10 mM of the selective Buj-Bello, A., Buchman, V.L., Horton, A., Rosenthal, A., and Davies,
inhibitor NO-711 (95% of total uptake). A.M. (1995). GDNF is an age-specific survival factor for sensory and
autonomic neurons. Neuron 15, 821±828.
[3H]Mazindol Binding to Brain Sections
Casper, D., Mytilineou, M., and Blum, J. (1991). EGF enhances theFrontal sections (14 mm) of the anterior, medial, and posterior level
survival of dopaminergic neurons in rat embryonic mesencephalicof the striatum were cut in a cryostat and thaw-mounted on gelatin-
primary cell culture. J. Neurosci. Res. 30, 372±381.coated microscopic slides. [3H]Mazindol autoradiography was done
Choi-Lundberg, D.L., and Bohn, M.C. (1995). Ontogeny and distribu-according to the procedure described by Javitch et al. (1984) using
tion of glial cell line-derived neurotrophic factor (GDNF) mRNA in60 nM [3H]mazindol (23.1 Ci/mmol; New England Nuclear±Dupont
rat. Dev. Brain Res. 85, 80±88.Research). Specific binding was defined by incubation in the pres-
ence of 10 mM nomifensine. Slides were exposed to X-ray film for Dewey, S.L., Smith, G.S., Logan, J., Alexoff, D., Ding, Y.-S., King,
2 weeks. Autoradiographs were analyzed using an image analysis P., Pappas, N., Brodie, J.D., and Ashby,C.R., Jr. (1995). Serotonergic
system: total striatal areas were outlined and specific optical densi- modulation of striatal dopamine measured with positron emission
ties (ODs) were determined by subtracting ODs measured on sec- tomography (PET) and in vivo microdialysis. J. Neurosci. 15,
tions incubated with nomifensin from the OD determined in corre- 821±829.
sponding sections incubated with [3H]mazindol alone. Dray, A., Davies, J., Oakley, N., and Tanner, T. (1976). Evidence for
the existence of a raphe projection to the substantia nigra in the
Tyrosine Hydroxylase Immunohistochemistry rat. Brain Res. 113, 45±57.
Frontal brain sections (45 mm) were cut on a sliding microtome
Dray, A., Davies, J., Oakley, N., Tongroach, P., and Velluci, S. (1978).and collected into PBS containing 0.02% NaN3. Every tenth section
The dorsal and medial raphe projections to the substantia nigra inspanning the striatum and every sixth section spanning the substan-
the rat: electrophysiological, biochemical and behavioral observa-tia nigra were stained for TH as described previously (Beck et al.,
tions. Brain Res. 151, 431±442.1995). To minimize section to section variations, during all steps of
the immunohistochemistry, sections from one control, cytochrome Ebendal, T., Tomac, A., Hoffer, B.J., and Olson, L. (1995). Glial cell
C and GDNF injected rat were processed simultaneously, using line-derived neurotrophic factor stimulates fiber formation and sur-
staining racks that permitted incubation of all sections in the same vival in cultured neurons from peripheral autonomic ganglia J. Neu-
solutions. Only sections that were stained together were used for rosci. Res. 40, 276±284.
histological comparisons. Ferre, S., Cortes, R., and Artigas, F. (1994). Dopaminergic regulation
of the serotonergic raphe-striatal pathway: microdialysis studies in
Acknowledgments freely moving rats. J. Neurosci. 14, 4839±4846.
Greenberg, D., Banerjee, S.P., Yamamura, H.I., and Snyder, S.H.Correspondence should be addressed to K. D. B. The study was
(1974). Drugs, neuro-transmitters, and schizophrenia. Science 184,supported by National Institutes of Health grants AG10480 (F. H.).
1243±1253.The costs of publication of this article were defrayed in part by
Henderson, C.E.,Phillips, H.S., Pollock, R.A., Davies, A.M., Lemeulle,the payment of page charges. This article must therefore be hereby
C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R.A., Koliatsos,marked ªadvertisementº in accordance with 18 USC Section 1734
V.E., and Rosenthal, A. (1994). GDNF: a potent survival factor forsolely to indicate this fact.
motoneurons present in peripheral nerve and muscle. Science 266,
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